Protalix BioTherapeutics, Inc. — Director's Dealing 2021

Jun 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protalix BioTherapeutics, Inc. (PLX)
CIK: 0001006281
Period of Report: 2021-06-02

Reporting Person: Dexcel Pharma Technologies Ltd. (10% Owner)
Reporting Person: Oren Dan (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-02	Common Stock	S	61211	$2.5576	Disposed	4494820	Direct
2021-06-03	Common Stock	S	857506	$2.2534	Disposed	3637314	Direct

Footnotes

F1: Dexcel Pharma Technologies Ltd ("DPT") and Dan Oren, DPT's Executive Chairman, are filing this Form 4 because they have beneficial ownership over common stock of Protalix BioTherapeutics, Inc. The shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT.

F2: The price reported in Column 4 is the weighted average price. The common shares were sold in multiple transactions at prices ranging from $2.530 to $2.565, inclusive.

F3: The price reported in Column 4 is the weighted average price. The common shares were sold in multiple transactions at prices ranging from $2.200 to $2.450, inclusive.

F4: The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.